APA (7th ed.) Citation

N, H., A, S., M, K., D, J., PJ, C., JJ, L., . . . HM, P. (2019). Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: The VCAT study. Leukemia & lymphoma, 60(9), 2122. https://doi.org/10.1080/10428194.2019.1579322

Chicago Style (17th ed.) Citation

N, Horvath, et al. "Phase 3 Study of Subcutaneous Bortezomib, Thalidomide, and Prednisolone Consolidation After Subcutaneous Bortezomib-based Induction and Autologous Stem Cell Transplantation in Patients with Previously Untreated Multiple Myeloma: The VCAT Study." Leukemia & Lymphoma 60, no. 9 (2019): 2122. https://doi.org/10.1080/10428194.2019.1579322.

MLA (9th ed.) Citation

N, Horvath, et al. "Phase 3 Study of Subcutaneous Bortezomib, Thalidomide, and Prednisolone Consolidation After Subcutaneous Bortezomib-based Induction and Autologous Stem Cell Transplantation in Patients with Previously Untreated Multiple Myeloma: The VCAT Study." Leukemia & Lymphoma, vol. 60, no. 9, 2019, p. 2122, https://doi.org/10.1080/10428194.2019.1579322.